Polycation-induced oligomerization and accelerated fibrillation of human α-synuclein in vitro

Protein Science

Volumn 12, Issue 4, 2003, Pages 702-707

  Goers, John ^a,b   Uversky, Vladimir N ^a,c   Fink, Anthony L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CALIFORNIA POLYTECHNIC STATE UNIVERSITY   (United States)

^c INSTITUTE FOR BIOLOGICAL INSTRUMENTATION   (Russian Federation)

Author keywords

synuclein; Aggregation; Electrostatic interactions; Fibrillation; Natively unfolded protein; Oligomerization; Parkinson's disease; Polycation

Indexed keywords

ALPHA SYNUCLEIN; POLYARGININE; POLYCATION; POLYETHYLENEIMINE; POLYLYSINE; POLYMER; SPERMINE;

ARTICLE; CATALYSIS; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; ELECTRIC ACTIVITY; IN VITRO STUDY; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN INTERACTION; PROTEIN STRUCTURE;

ALPHA-SYNUCLEIN; CIRCULAR DICHROISM; HUMANS; MICROSCOPY, ELECTRON; NERVE TISSUE PROTEINS; POLYAMINES; POLYMERS; SYNUCLEINS;

EID: 0037378356     PISSN: 09618368     EISSN: None     Source Type: Journal    
DOI: 10.1110/ps.0230903     Document Type: Article

References (38)

1. Cardin, AD. and Weintraub. H.J. 1989. Molecular modeling of protein-glycosaminoglycan interactions. Arteriosclerosis 9: 21-32.
2. Cohlberg, J.A., Li, J., Uversky, V.N., and Fink, A.L. 2002. Heparin and other glycosamino-glycans stimulate the formation of amyloid fibrils from α-synuclein in vitro. Biochemistry 41: 1502-1511.
3. Conway, K.A., Harper, J.D., and Lansbury, P.T. 1998. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease. Nat. Med. 4: 1318-1320,
4. Conway, K.A., Lee, S.J., Rochet, J.C., Ding, T.T., Williamson, R.E., and Lansbury, Jr., P.T., 2000. Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. 97: 571-576.
5. Crowther, R.A., Jakes, R., Spillantini, M.G., and Goedert, M. 1998. Synthetic filaments assembled from C-terminally truncated α-synuclein. FEBS Lett. 436: 309-312.
6. Crowther, R.A., Daniel, S.E., and Goedert M. 2000. Characterization of isolated a-synuclein filaments from substantia nigra of Parkinson's disease brain. Neurosci. Lett. 292: 128-130.
7. Dunker, A.K. and Obradovic, Z. 2001. The protein trinity-linking function and disorder. Nat. Biotechnol. 19: 805-806.
8. Dunker, A.K., Lawson, J.D., Brown, C.J., Williams, R.M., Romero, P., Oh, J.S., Oldfield, C.J., Campen, A.M., Ratliff, CM., Hipps, K.W., et al. 2001. Intrinsically disordered proteins. J. Mol. Graph. Model. 19: 26-59.
9. Dunker, A.K., Brown, C.J., Lawson, J.D., Iakoucheva, L.M., and Obradovic, Z. 2002a. Intrinsic disorder and protein function. Biochemistry 41: 6573-6582.
10. Dunker, A.K., Brown, C.J., and Obradovic, Z. 2002b. Identification and function of usefully disordered proteins. Adv. Protein Chem. 62: 25-49.
11. Dyson, H.J. and Wright, P.E. 2002. Coupling of folding and binding for unstructured proteins. Curr. Opin. Struct. Biol. 12: 54-60.
12. Eliezer, D., Kutluay, E., Bussell, Jr., R., and Browne, G. 2001. Conformational properties of α-synuclein in its free and lipid-associated states. J. Mol. Biol. 307: 1061-1073.
13. Giasson, B.I., Uryu, K., Trojanowski, J.Q., and Lee, V.M. 1999. Mutant and wild type human α-synucleins assemble into elongated filaments with distinct morphologies in vitro. J. Biol. Chem. 274: 7619-7622.
14. Goedert, M. 2001. Parkinson's disease and other a-synucleinopathies. Clin. Chem. Lab Med. 39: 308-312.
15. Gomes-Trolin, C., Nygren, I., Aquilonius, S. M., and Askmark, H. 2002. Increased red blood cell polyamines in ALS and Parkinson's disease. Exp. Neurol. 177: 515-520.
16. Iwai, A., Masliah, E., Yoshimoto, M., Ge, N., Flanagan, L., de Silva. H.A., Kittel, A., and Saitoh, T. 1995. The precursor protein of non-A β component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14: 467-475.
17. Jakes, R., Spillantini, M.G., and Goedert. M. 1994. Identification of two distinct synucleins from human brain. FEBS Lett. 345: 27-32.
18. Li, J., Uversky, V.N., and Fink, A.L. 2001. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation and fibrillation of human α-synuclein. Biochemistry 40: 11604-11613.
19. Lucking, C.B. and Brice, A. 2000. α-Synuclein and Parkinson's disease. Cell Mol. Life Sci. 57: 1894-1908.
20. Manning-Bog, A.B., McCormack, A.L., Li, J., Uversky, V.N., Fink, A.L., and Di Monte, D.A. 2002. The herbicide paraquat causes upregulation and aggregation of α-synuclein in mice. J. Biol. Chem. 277: 1641-1644.
21. Maroteaux, L., Campanelli, J.T., and Scheller, R.H. 1988. Synuclein: A neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 8: 2804-2815.
22. Narhi, L., Wood, S.J., Stevenson, S., Jiang, Y., Wu, G.M., Anafi, D., Kaufman, S.A., Martin, F., Sitney, K., Denis, P., et al. 1999. Both familial Parkinson's disease mutations accelerate α-synuclein aggregation. J. Biol. Chem. 274: 9843-9846.
23. Nielsen, L., Khurana, R., Coats, A., Frokjaer, S., Brange, J., Vyas, S., Uversky, V.N., and Fink, A.L. 2001. The effect of environmental factors on the kinetics of insulin fibril formation: Elucidation of the molecular mechanism. Biochemistry 40: 6036-6046.
24. Plaxco, K.W. and Gross, M. 1997. The importance of being unfolded. Nature 386: 657-659.
25. Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R., and Goedert, M. 1997. α-synuclein in Lewy bodies. Nature 388: 839-840.
26. Trojanowski, J.Q., Goedert, M., Iwatsubo, T., and Lee, V.M. 1998. Fatal attractions: Abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia. Cell Death Differ 5: 832-837.
27. Uversky, V.N. 2002a. What does it mean to be natively unfolded? Eur. J. Biochem. 269: 2-12.
28. -. 2002b. Natively unfolded proteins: A point where biology waits for physics. Protein Sci. 11: 739-756.
29. Uversky, V.N., Gillespie, J.R., and Fink, A.L. 2000. Why are "natively unfolded" proteins unstructured under the physiological conditions? Proteins Struct. Funct. Genet. 42: 415-327.
30. Uversky, V.N., Li, J., and Fink, A.L. 2001a. Evidence for a partially-folded intermediate in α-synuclein fibrillation. J. Biol. Chem. 276: 10737-10744.
31. -. 2001b. Metal-triggered structural transformations, aggregation and fibril formation of human α-synuclein. A possible molecular link between Parkinson's disease and heavy metal exposure. J. Biol. Chem. 276: 44284-44296.
32. -. 2001c. Pesticides directly accelerate the rate of α-synuclein fibril formation: A possible factor in Parkinson's disease. FEBS Lett. 500: 105-108.
33. Uversky, V.N., Li, J., Bower, K., and Fink, A.L. 2002a. Synergistic effects of pesticides and metals on the fibrillation of α-synuclein: Implications for Parkinson's disease. Neurotoxicology 23: 527-536.
34. Uversky, V.N., Yamin, G., Souillac, P.O., Goers, J., Glaser, C.B., and Fink, A.L. 2002b. Methionine oxidation inhibits fibrillation of human α-synuclein in vitro. FEBS Lett. 517: 239-244.
35. Vivo, M., de Vera, N., Cortes, R., Mengod, G., Camon, L., and Martinez, E. 2001. Polyamines in the basal ganglia of human brain. Influence of aging and degenerative movement disorders. Neurosci. Lett. 304: 107-111.
36. Weinreb, P.H., Zhen, W.G., Poon, A.W., Conway, K.A., and Lansbury, Jr., P.T. 1996. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 35: 13709-13715.
37. Wood, S.J., Wypych, J., Stevenson, S., Louis, J.C., Citron, M., and Biere, A.L. 1999. α-Synuclein fibrillogenesis is nucleation-dependent - Implications for the pathogenesis of Parkinson's disease. J. Biol. Chem. 274: 19509-19512.
38. Wright, P.E. and Dyson, H.J. 1999. Intrinsically unstructured proteins: Reassessing the protein structure-function paradigm. J. Mol. Biol. 293: 321-331.